Treatment of experimental myocarditis via modulation of the renin-angiotensin system

Melvin D Daniels1, Kenneth V Hyland, David M Engman

  • 1Department of Pathology and Microbiology-Immunology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA. d-engman@northwestern.edu

Insights

Drugs targeting the renin-angiotensin system, like ACE inhibitors and ARBs, show promise for treating myocarditis. They reduce inflammation and fibrosis without broad immune suppression, aiding recovery from heart inflammation.

Area of Science:

  • Cardiovascular Research
  • Immunology
  • Pharmacology

Background:

  • The renin-angiotensin system regulates vascular tone and is targeted by drugs for hypertension and cardiomyopathy.
  • Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor antagonists (ARBs) also impact inflammation, adhesion molecules, and fibrosis.
  • Myocarditis, an inflammatory heart condition, presents a potential therapeutic target for these agents.

Purpose of the Study:

  • To review the efficacy of ACEIs and ARBs in experimental models of infectious and autoimmune myocarditis.
  • To assess the therapeutic potential of renin-angiotensin system modulation for inflammatory heart disease.

Main Methods:

  • Review of studies using mouse models of virus-induced myocarditis.
  • Review of studies using mouse models of parasite-induced myocarditis.
  • Review of studies using mouse models of autoimmune cardiomyopathy.

Main Results:

  • ACEIs and ARBs demonstrate efficacy in treating various forms of experimental myocarditis.
  • These drugs modulate key inflammatory and fibrotic pathways in the heart.
  • Renin-angiotensin modulation appears to downregulate autoimmunity without causing detrimental immune suppression.

Conclusions:

  • Evidence strongly supports using renin-angiotensin modulation for myocarditis treatment.
  • This approach offers a potential strategy for managing inflammatory heart diseases.
  • Therapeutic benefits include reduced inflammation and fibrosis with preserved immune function.

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Myocarditis IV: Nursing Management01:22

Myocarditis IV: Nursing Management

Myocarditis is an inflammatory condition of the myocardium requiring meticulous nursing management for optimal patient outcomes. Effective management begins with a thorough assessment of the patient's medical history, paying close attention to past infections, autoimmune disorders, travel history, and exposure to toxins or drugs. Recent viral infections and systemic diseases are particularly relevant due to their potential role in triggering myocarditis.Physical Examination and MonitoringThe...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...